ObalonBalloon Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • ObalonBalloon's estimated annual revenue is currently $5.8M per year.(i)
  • ObalonBalloon's estimated revenue per employee is $303,842

Employee Data

  • ObalonBalloon has 19 Employees.(i)
  • ObalonBalloon grew their employee count by 0% last year.

ObalonBalloon's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$20.3M7920%N/AN/A
#2
$8.5M3111%N/AN/A
#3
$4.5M13-13%N/AN/A
#4
$8M25-4%N/AN/A
#5
$5.3M16-6%N/AN/A
#6
$54.2M163-8%N/AN/A
#7
$12M55-17%N/AN/A
#8
$10M30-9%N/AN/A
#9
$30.1M12022%N/AN/A
#10
$14.1M43-7%N/AN/A
Add Company

What Is ObalonBalloon?

Obalon is an engineering-driven medical technology company with a singular focus on innovative, high-quality gastric balloon technology. Located in San Diego, California, the technical team at Obalon has a long history of working closely with leading clinicians to develop innovative medical products that revolutionize treatment of chronic disease.

keywords:N/A

N/A

Total Funding

19

Number of Employees

$5.8M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

ObalonBalloon News

2022-04-17 - Intragastric Balloons Market Size And Forecast | Silimed, Apollo ...

Silimed, Apollo Endosurgery, Medsil, Districlass Medical, Obalon Therapeutics, Allurion Technologies, Lexel, Helioscopie Medical Implants,...

2022-04-13 - Worldwide Intragastric Balloons Industry to 2029 - Key Drivers ...

The intragastric balloons types are categorized into single balloons, ... Fengh Medical, Medsil, Obalon Therapeutics, Phagia Technologies,...

2022-03-30 - ReShape Lifesciences Inc. (RSLS) CEO Bart Bandy on Q4 2021 Results - Earnings Call Transcript

... and regulatory requirements, manufacturing viability and quality system control necessary for reintroducing the Obalon Balloon System.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.3M190%N/A
#2
$7.5M190%N/A
#3
N/A1927%N/A
#4
$1.7M19N/AN/A
#5
$6M200%N/A